These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35986565)

  • 21. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Seephetdee C; Bhukhai K; Buasri N; Leelukkanaveera P; Lerdwattanasombat P; Manopwisedjaroen S; Phueakphud N; Kuhaudomlarp S; Olmedillas E; Saphire EO; Thitithanyanont A; Hongeng S; Wongtrakoongate P
    Antiviral Res; 2022 Aug; 204():105370. PubMed ID: 35772601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
    Ma Q; Li M; Ma L; Zhang C; Zhang H; Zhong H; Wen J; Wang Y; Yan Z; Xiong W; Wu L; Guo J; Yang W; Yang Z; Zhang B
    Front Immunol; 2023; 14():1195299. PubMed ID: 37292197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
    Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    Zhang T; Wang Z; Yang J; Xu X
    J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.
    Rudi E; Martin Aispuro P; Zurita E; Gonzalez Lopez Ledesma MM; Bottero D; Malito J; Gabrielli M; Gaillard E; Stuible M; Durocher Y; Gamarnik AV; Wigdorovitz A; Hozbor D
    Front Immunol; 2022; 13():1020159. PubMed ID: 36248791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
    Corleis B; Hoffmann D; Rauch S; Fricke C; Roth N; Gergen J; Kovacikova K; Schlottau K; Halwe NJ; Ulrich L; Schön J; Wernike K; Widera M; Ciesek S; Mueller SO; Mettenleiter TC; Maione D; Petsch B; Beer M; Dorhoi A
    Nat Commun; 2023 Feb; 14(1):816. PubMed ID: 36781853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omicron infection increases IgG binding to spike protein of predecessor variants.
    Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
    J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
    Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
    J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants.
    Gao F; Zheng M; Fan J; Ding Y; Liu X; Zhang M; Zhang X; Dong J; Zhou X; Luo J; Li X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2186110. PubMed ID: 36882925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern.
    Cao L; Guo J; Li H; Ren H; Xiao K; Zhang Y; Zhu S; Song Y; Zhao W; Wu D; Chen Z; Zhang Y; Xia B; Ji T; Yan D; Wang D; Yang Q; Zhou Y; Li X; Hou Z; Xu W
    Microbiol Spectr; 2023 Feb; 11(2):e0268722. PubMed ID: 36847495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
    Sun C; Yuan RY; Xie C; Sun JF; Fang XY; Hu YS; Yu XH; Liu Z; Zeng MS; Kang YF
    J Virol; 2022 Jul; 96(13):e0038322. PubMed ID: 35699445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Chalkias S; Eder F; Essink B; Khetan S; Nestorova B; Feng J; Chen X; Chang Y; Zhou H; Montefiori D; Edwards DK; Girard B; Pajon R; Dutko FJ; Leav B; Walsh SR; Baden LR; Miller JM; Das R
    Nat Med; 2022 Nov; 28(11):2388-2397. PubMed ID: 36202997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.